NYSEMKT: CYBNCybin Inc Stock
$7.35-0.10 (-1.34%)
Updated Apr 17, 2025
CYBN Price
$7.35
Fair Value Price
N/A
Market Cap
$147.01M
52 Week Low
$4.81
52 Week High
$14.44
P/E
-2.16x
P/B
0.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$72.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$70M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CYBN Overview
Cybin Inc. is a biotechnology company focused on researching and progressing psychedelic therapeutics for psychiatric disorders. It has also developed EMBARK, psychedelic-assisted psychotherapy. The company's development pipeline includes CYB003, CYB004, and CYB005, among others. The company was founded in 2019 and is headquartered in Toronto, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CYBN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CYBN
Ranked#346 of 463
Ranked#346 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important CYBN news, forecast changes, insider trades & much more!
CYBN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CYBN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CYBN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CYBN is good value based on its book value relative to its share price (0.88x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
CYBN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CYBN due diligence checks available for Premium users.
Valuation
CYBN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.16x
Industry
-177.72x
Market
27.98x
CYBN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.88x
Industry
4.05x
CYBN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CYBN's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.3M
Profit Margin
0%
CYBN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$176.1M
Liabilities
$9.2M
Debt to equity
0.06
CYBN's short-term assets ($116.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYBN's short-term assets ($116.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYBN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.8M
Investing
-$210.4k
Financing
-$124.3k
CYBN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CYBN vs Biotech Stocks
Cybin Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.